NCT00242723 2026-04-17
Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining
National Institutes of Health Clinical Center (CC)
Recruiting
Clinical Trials
322 trialsNCT02535312 2026-04-17
Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT05960773 2026-04-17
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma
National Institutes of Health Clinical Center (CC)
Phase 2 Suspended
NCT04491942 2026-04-13
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT06362369 2026-04-13
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
7 Hills Pharma, LLC
Phase 1/2 Recruiting
NCT07443020 2026-04-07
RIOT 4B
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Phase 1 Recruiting
NCT07510815 2026-04-06
DUAL-MESO-NK
Beijing Biotech
Phase 1/2 Recruiting
NCT07277413 2026-04-03
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
IDEAYA Biosciences
Phase 1 Recruiting
NCT06097728 2026-04-02
eVOLVE-Meso
AstraZeneca
Phase 3 Recruiting
NCT03126630 2026-04-01
Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT06251310 2026-04-01
SW-682 in Advanced Solid Tumors
SpringWorks Therapeutics, Inc.
Phase 1 Recruiting
NCT01064648 2026-03-31
Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT05655078 2026-03-30
HIT-Meso
University College, London
Phase NA Recruiting
NCT06971848 2026-03-30
ETCABIO
University Hospital, Angers
Phase NA Not yet recruiting
NCT03678350 2026-03-27
Light Dosimetry for Photodynamic Therapy With Porfimer Sodium in Treating Participants With Malignant Mesothelioma or Non-Small Cell Lung Cancer With Pleural Disease Undergoing Surgery
Roswell Park Cancer Institute
Phase 1 Completed
NCT03420963 2026-03-20
Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT06654050 2026-03-17
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn
NCT06840834 2026-03-16
Bi-MAPS
Intergroupe Francophone de Cancerologie Thoracique
Phase 2 Recruiting
NCT04897022 2026-03-12
A Study of Pembrolizumab and Radiation Therapy in People With Mesothelioma
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT03074513 2026-03-11
Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT02959463 2026-03-06
Pembrolizumab After Radiation Therapy in Treating Patients With Pleural Malignant Mesothelioma
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT00797719 2026-03-05
Short Neoadjuvant Hemithoracic IMRT for MPM
University Health Network, Toronto
Phase 1/2 Completed
NCT01843374 2026-03-05
Tremelimumab
MedImmune LLC
Phase 2 Active not recruiting
NCT07449624 2026-03-04
From Presentation to Diagnosis: Patterns of Pleural Effusion
Mansoura University Hospital
Completed
NCT06051695 2026-02-20
EVEREST-2
A2 Biotherapeutics Inc.
Phase 1/2 Recruiting
NCT06566079 2026-02-17
Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors
InSilico Medicine Hong Kong Limited
Phase 1 Recruiting
NCT07126509 2026-02-17
Partial Pleurectomy (Surgery) for Unresectable Pleural Mesothelioma
University of Chicago
Phase NA Recruiting
NCT07403630 2026-02-17
IT-TCP POS
Azienda Ospedaliero-Universitaria di Parma
Phase NA Recruiting
NCT04981119 2026-02-13
BASECAMP-1
A2 Biotherapeutics Inc.
Recruiting
NCT07234058 2026-02-11
LAG-MAPS
Intergroupe Francophone de Cancerologie Thoracique
Phase 2 Not yet recruiting
NCT05568680 2026-02-10
SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma
Verismo Therapeutics
Phase 1 Recruiting
NCT02662504 2026-02-05
MesoPDT
University Hospital, Lille
Phase 2 Completed
NCT05136677 2026-01-23
CheckMate 6DW
Bristol-Myers Squibb
Phase 2 Completed
NCT04334759 2026-01-22
DREAM3R
PrECOG, LLC.
Phase 3 Completed
NCT03269227 2026-01-16
MesoRT
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase NA Active not recruiting
NCT07192900 2026-01-15
(RIOT 4A)
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Phase 1 Recruiting
NCT06155279 2026-01-13
CHIMERA
Istituto Oncologico Veneto IRCCS
Phase 2 Active not recruiting
NCT05380713 2025-12-29
......SMARTEST Trial......
University Health Network, Toronto
Phase 2 Completed
NCT05005429 2025-12-23
BIMES
Fundación GECP
Phase 2 Completed
NCT07282873 2025-12-22
Study of TYK-01054 Capsules in Patients With Advanced Solid Tumors
TYK Medicines, Inc
Phase 1/2 Not yet recruiting
NCT02611037 2025-12-18
Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT03760575 2025-12-04
Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)
Abramson Cancer Center at Penn Medicine
Phase 1 Recruiting
NCT05795595 2025-11-26
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors
CRISPR Therapeutics
Phase 1/2 Completed
NCT06603987 2025-11-19
Using CICS-1 and SPM-011 and ï¼»18Fï¼½FBPA Commissioned by CICS and Sumitomo Heavy Industries and STELLA PHARMA
Stella Pharma Corporation
Phase 1/2 Enrolling by invitation
NCT03007030 2025-11-10
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT03228537 2025-11-10
Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT05337735 2025-10-09
A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers
M.D. Anderson Cancer Center
Phase 2 Suspended
NCT05308966 2025-10-06
MESO-IMMUNE
Groupe Francais De Pneumo-Cancerologie
Completed
NCT04914897 2025-10-02
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)
Sanofi
Phase 2 Terminated
NCT04400539 2025-09-25
IMPALA
University Hospital, Lille
Phase 2 Recruiting